The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Feb 13

PMID 32046053

Citations 26

Authors

Francesca Chiarini

Francesca Paganelli

Alberto M Martelli

Camilla Evangelisti

Affiliations

Soon will be listed here.

Abstract

Acute lymphoblastic leukemia (ALL) is an aggressive hematologic neoplastic disorder that arises from the clonal expansion of transformed T-cell or B-cell precursors. Thanks to progress in chemotherapy protocols, ALL outcome has significantly improved. However, drug-resistance remains an unresolved issue in the treatment of ALL and toxic effects limit dose escalation of current chemotherapeutics. Therefore, the identification of novel targeted therapies to support conventional chemotherapy is required. The Wnt/β-catenin pathway is a conserved signaling axis involved in several physiological processes such as development, differentiation, and adult tissue homeostasis. As a result, deregulation of this cascade is closely related to initiation and progression of various types of cancers, including hematological malignancies. In particular, deregulation of this signaling network is involved in the transformation of healthy HSCs in leukemic stem cells (LSCs), as well as cancer cell multi-drug-resistance. This review highlights the recent findings on the role of Wnt/β-catenin in hematopoietic malignancies and provides information on the current status of Wnt/β-catenin inhibitors with respect to their therapeutic potential in the treatment of ALL.

Citing Articles

The dynamic interaction of pediatric ALL cells and MSCs: influencing leukemic cell survival and modulating MSC β-catenin expression.

Ozdemir-Sanci T, Piskin I, Koksal Y, Cayli S, Ozbek N, Ozguner H Histochem Cell Biol. 2025; 163(1):26.

PMID: 39836255 PMC: 11750926. DOI: 10.1007/s00418-025-02353-w.

Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.

Zhao L, Sun L, Kong D, Cao R, Guo Z, Guo D Ann Hematol. 2024; 104(1):489-501.

PMID: 39607486 PMC: 11868301. DOI: 10.1007/s00277-024-06110-2.

A systematic review of the anti-inflammatory and anti-fibrotic potential of human umbilical cord mesenchymal stem cells-derived exosomes in experimental models of liver regeneration.

Puspita R, Jusuf A, Antarianto R, Sianipar I Mol Biol Rep. 2024; 51(1):999.

PMID: 39302506 DOI: 10.1007/s11033-024-09929-0.

A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma.

Ding Y, Huang K, Sun C, Liu Z, Zhu J, Jiao X Sci Rep. 2024; 14(1):21184.

PMID: 39261532 PMC: 11391086. DOI: 10.1038/s41598-024-72121-8.

New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies.

Nag J, Appasamy P, Malka H, Sedley S, Bar-Shavit R Int J Mol Sci. 2024; 25(15).

PMID: 39125653 PMC: 11311281. DOI: 10.3390/ijms25158083.

References

Evangelisti C, Chiarini F, Cappellini A, Paganelli F, Fini M, Santi S . Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. J Cell Physiol. 2020; 235(6):5413-5428. DOI: 10.1002/jcp.29429. View

Fong C, Gilan O, Lam E, Rubin A, Ftouni S, Tyler D . BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015; 525(7570):538-42. PMC: 6069604. DOI: 10.1038/nature14888. View

Stamos J, Chu M, Enos M, Shah N, Weis W . Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6. Elife. 2014; 3:e01998. PMC: 3953950. DOI: 10.7554/eLife.01998. View

Ahn Y, Sanderson B, Klein O, Krumlauf R . Inhibition of Wnt signaling by Wise (Sostdc1) and negative feedback from Shh controls tooth number and patterning. Development. 2010; 137(19):3221-31. PMC: 6512258. DOI: 10.1242/dev.054668. View

Guo X, Zhang R, Liu J, Li M, Song C, Dovat S . Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia. PLoS One. 2015; 10(5):e0125429. PMC: 4420493. DOI: 10.1371/journal.pone.0125429. View

Luis T, Weerkamp F, Naber B, Baert M, de Haas E, Nikolic T . Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation. Blood. 2008; 113(3):546-54. DOI: 10.1182/blood-2008-06-163774. View

Koo B, Spit M, Jordens I, Low T, Stange D, van de Wetering M . Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012; 488(7413):665-9. DOI: 10.1038/nature11308. View

Mazieres J, You L, He B, Xu Z, Lee A, Mikami I . Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene. 2005; 24(34):5396-400. DOI: 10.1038/sj.onc.1208568. View

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

10.

Wu W, Glinka A, Delius H, Niehrs C . Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr Biol. 2001; 10(24):1611-4. DOI: 10.1016/s0960-9822(00)00868-x. View

11.

Rathert P, Roth M, Neumann T, Muerdter F, Roe J, Muhar M . Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015; 525(7570):543-547. PMC: 4921058. DOI: 10.1038/nature14898. View

12.

Li L, Mao J, Sun L, Liu W, Wu D . Second cysteine-rich domain of Dickkopf-2 activates canonical Wnt signaling pathway via LRP-6 independently of dishevelled. J Biol Chem. 2001; 277(8):5977-81. DOI: 10.1074/jbc.M111131200. View

13.

Luis T, Ichii M, Brugman M, Kincade P, Staal F . Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia. 2011; 26(3):414-21. PMC: 3378318. DOI: 10.1038/leu.2011.387. View

14.

Bienz M . Signalosome assembly by domains undergoing dynamic head-to-tail polymerization. Trends Biochem Sci. 2014; 39(10):487-95. DOI: 10.1016/j.tibs.2014.08.006. View

15.

Heidel F, Bullinger L, Feng Z, Wang Z, Neff T, Stein L . Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 2012; 10(4):412-24. PMC: 3339412. DOI: 10.1016/j.stem.2012.02.017. View

16.

Faderl S, OBrien S, Pui C, Stock W, Wetzler M, Hoelzer D . Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010; 116(5):1165-76. PMC: 5345568. DOI: 10.1002/cncr.24862. View

17.

Schubbert S, Cardenas A, Chen H, Garcia C, Guo W, Bradner J . Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia. Cancer Res. 2014; 74(23):7048-59. PMC: 4258248. DOI: 10.1158/0008-5472.CAN-14-1470. View

18.

Saenz D, Fiskus W, Manshouri T, Mill C, Qian Y, Raina K . Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2018; 33(6):1373-1386. DOI: 10.1038/s41375-018-0334-3. View

19.

Seshagiri S, Stawiski E, Durinck S, Modrusan Z, Storm E, Conboy C . Recurrent R-spondin fusions in colon cancer. Nature. 2012; 488(7413):660-4. PMC: 3690621. DOI: 10.1038/nature11282. View

20.

Luis T, Naber B, Roozen P, Brugman M, de Haas E, Ghazvini M . Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell. 2011; 9(4):345-56. DOI: 10.1016/j.stem.2011.07.017. View